0 0 0 0 0 0 0 0.0022098052214542
Sign Up Today X
Thanks for submitting the form.
Stockreport

Alumis: Could This Broken Immunology IPO Become The Next Amgen? [Seeking Alpha]

Amgen Inc. (AMGN)  More Company Research Source: Seeking Alpha
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Summary With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can get it around 30% under the June 28th IPO price. Alumis is backed by prominent healthcare hedge funds such as Baker Brothers, VenBio, and Cormorant Asset Management. But do the potential gains justify the risk? We take an in-depth look at the company's pipeline and trial results and deliver our verdict. Toshe_O Introduction Alumis ( NASDAQ: ALMS ), a biotech with a pair of immunology drugs in advanced clinical testing debuted on the Nasdaq on June 28. The company raised $250 million from the downsized IPO, offering investors 13.125 million shares at $16 per share while adding $40 million through a private placement to one of its current investors, AyurMaya Capital Management. In spite of an A-list of underwriters (Morgan Stanley, Leerink Partners, Cantor Fitzgerald, [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

Alumis: Could This Broken Immunology IPO Become The Next Amgen? [Seeking Alpha]

Amgen Inc.  (AMGN) 
More Company Research Source: Seeking Alpha
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Summary With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can get it around 30% under the June 28th IPO price. Alumis is backed by prominent healthcare hedge funds such as Baker Brothers, VenBio, and Cormorant Asset Management. But do the potential gains justify the risk? We take an in-depth look at the company's pipeline and trial results and deliver our verdict. Toshe_O Introduction Alumis ( NASDAQ: ALMS ), a biotech with a pair of immunology drugs in advanced clinical testing debuted on the Nasdaq on June 28. The company raised $250 million from the downsized IPO, offering investors 13.125 million shares at $16 per share while adding $40 million through a private placement to one of its current investors, AyurMaya Capital Management. In spite of an A-list of underwriters (Morgan Stanley, Leerink Partners, Cantor Fitzgerald, [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS